![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
chuka_lisДанные из Малайзии, где проверили ретроспективно, как влияет время, прошедшее после полной прививки, на эффективность вакцин: от инфекции, тяжелого ковида и смерти. То есть о том, как затухает иммунитет после иммунизации (тк прививки делают для того, чтобы выработался иммунитет).
Авторы проанализировали случаи ковида, среди привитых и нет, и, кроме того, привитых они разделили на 2 группы- те, кто привился рано (апрель-июнь) и у кого прошло больше времени с момента полной прививки (3-5 мес), и тех, кто привился поздно (июль-август), и у кого иммунитет посвежее (1-2 мес). Проверяли для 2 типов вакцин- файзера и коронавака. Все случаи, которые вошли в исследование- произошли в течение сентября 2021 года. Всего в этот период у них случилось 246 029 случаев ковида среди тех кому старше 18, среди которых 163902 - у полностью привитых. Всего на это время в стране было привито 9 927350 человек в тех временных рамках и теми вакцинами, о которых речь (около 10 млн, среди которых в сентябре заболел ковидом (пробои) примерно 1.6%)
Сравниваем осложнения у непривитых и привитых, спустя разное время после прививки:
Эффективность вакцин:
Авторы разбили и по возрастам, и, ничего удивительного- те, кому за 65, теряли иммунность и у них понижалась эффективность вакцины чуть быстрее.
Так что эффективность вакцины выше всего- от смерти, и более менее держиется в исследованные сроки, а вот защита для "подхватить и заболеть"- снижается.
Файзер показал себя эффективнее коронавака.
Evaluation of vaccine effectiveness over time against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) is important. Evidence on effectiveness over time for the CoronaVac vaccine is lacking despite its widespread use globally. In Malaysia, a diverse set-up of COVID-19 vaccines was rolled out nationwide, and the waning of vaccine protection is a concern. We aimed to investigate and compare waning vaccine effectiveness against COVID-19 infections, COVID-19 related ICU admission and COVID-19 related deaths for BNT162b2 and CoronaVac vaccines. In this observational study, we consolidated nationally representative data on COVID-19 vaccination and patients′ outcomes. Data on all confirmed COVID-19 cases from 1 to 30 September 2021 were used to compare vaccine effectiveness between the ′early′ group (fully vaccinated in April to June 2021) and the ′late′ group (fully vaccinated in Jul to Aug 2021). We used a negative binomial regression model to estimate vaccine effectiveness against COVID-19 infections for both ′early′ and ′late′ groups, by comparing the rates of infection for individuals vaccinated in the two different periods relative to the unvaccinated. Among confirmed COVID-19 cases, we used logistic regression to estimate and compare vaccine effectiveness against ICU admission and deaths between the two different periods. For BNT162b2, vaccine effectiveness against COVID-19 infections declined from 90.8% (95% CI 89.4, 92.0) in the late group to 79.1% (95% CI 75.8, 81.9) in the late group. Vaccine effectiveness for BNT162b2 against ICU admission and deaths were comparable between the two different periods. For CoronaVac, vaccine effectiveness waned against COVID-19 infections from 74.4% in the late group (95% CI 209 70.4, 77.8) to 30.0% (95% CI 18.4, 39.9) in the early group. It also declined significantly against ICU admission, dropping from 56.1% (95% CI 51.4, 60.2) to 29.9% (95% CI 13.9, 43.0). For deaths, however, CoronaVac′s effectiveness did not wane after three to five months of full vaccination. Vaccine effectiveness against COVID-19 infections waned after three to five months of full vaccination for both BNT162b2 and CoronaVac in Malaysia. Additionally, for CoronaVac, protection against ICU admission declined as well. Evidence on vaccine effectiveness over time informs evolving policy decisions on vaccination.
After excluding individuals with infections outside of the study period and recipients of other vaccines, 9,927,350 individuals were fully vaccinated with homologous BNT162b2 or CoronaVac vaccines. There were 246,029 confirmed COVID-19 cases throughout the outcome observation period in September 2021, of which 163,902 were vaccinated, and 82,127 were unvaccinated. For BNT162b2, overall vaccine effectiveness against ICU admission and death were largely similar between the late and early groups. Overall vaccine effectiveness against ICU admissions dropped slightly from 86·0% (95% CI 82·8, 88·6) in the late group to 79·3% (95% CI 74·3, 83·4) in the early group. When stratified by age groups, the decline was stronger among cases aged 60 years and above, for which effectiveness fell to 57·2% (95% CI 43·4, 67·6). For deaths, vaccine effectiveness among both early and late groups remained at around 90%, suggesting no waning of effectiveness. When stratified by age, effectiveness against death among cases aged 60 years and above was lower than the other age groups, but similarly did not wane.For CoronaVac, vaccine effectiveness waned for ICU admissions, but remained stable against deaths. Moreover, CoronaVac’s effectiveness estimates were generally lower compared to BNT162b2. For ICU admissions, vaccine effectiveness declined from 56·1% (95% CI 51·4, 60·2) in the late group to 29·9% (95% CI 13·9, 43·0) in the early group. The waning of effectiveness against ICU admissions was observed in all age groups. In contrast, vaccine effectiveness against death remained at above 75%. The age-stratified analysis shows that CoronaVac’s effectiveness against death remained stable for the older age groups (40 to 59 years old, 60 years and above), while for those aged 18 to 39 years old, the number of deaths were too small to estimate reliably.
Авторы проанализировали случаи ковида, среди привитых и нет, и, кроме того, привитых они разделили на 2 группы- те, кто привился рано (апрель-июнь) и у кого прошло больше времени с момента полной прививки (3-5 мес), и тех, кто привился поздно (июль-август), и у кого иммунитет посвежее (1-2 мес). Проверяли для 2 типов вакцин- файзера и коронавака. Все случаи, которые вошли в исследование- произошли в течение сентября 2021 года. Всего в этот период у них случилось 246 029 случаев ковида среди тех кому старше 18, среди которых 163902 - у полностью привитых. Всего на это время в стране было привито 9 927350 человек в тех временных рамках и теми вакцинами, о которых речь (около 10 млн, среди которых в сентябре заболел ковидом (пробои) примерно 1.6%)
Сравниваем осложнения у непривитых и привитых, спустя разное время после прививки:
| Тяжесть\ Доля попавших под раздачу, % | Непривитые | Файзер, ранняя группа | Файзер, поздняя группа | Коронавак, ранняя группа | Коронавак, поздняя группа |
| Реанимация | 2 | 0.4 | 0.3 | 1.8 | 0.8 |
| Смерть | 4.1 | 0.4 | 0.6 | 1.4 | 0.7 |
Эффективность вакцин:
| Тип вакцины\ эффективность вакцины, % | От инфекции | От реанимации | От смерти |
| Файзер, ранняя группа | 79.1 | 79.3 | 90 |
| Файзер, поздняя группа | 90.8 | 86 | 90 |
| Коронавак, ранняя группа | 30 | 29.9 | 75 |
| коронавак, поздняя группа | 74.4 | 56.1 | 75 |
Авторы разбили и по возрастам, и, ничего удивительного- те, кому за 65, теряли иммунность и у них понижалась эффективность вакцины чуть быстрее.
Так что эффективность вакцины выше всего- от смерти, и более менее держиется в исследованные сроки, а вот защита для "подхватить и заболеть"- снижается.
Файзер показал себя эффективнее коронавака.
Evaluation of vaccine effectiveness over time against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) is important. Evidence on effectiveness over time for the CoronaVac vaccine is lacking despite its widespread use globally. In Malaysia, a diverse set-up of COVID-19 vaccines was rolled out nationwide, and the waning of vaccine protection is a concern. We aimed to investigate and compare waning vaccine effectiveness against COVID-19 infections, COVID-19 related ICU admission and COVID-19 related deaths for BNT162b2 and CoronaVac vaccines. In this observational study, we consolidated nationally representative data on COVID-19 vaccination and patients′ outcomes. Data on all confirmed COVID-19 cases from 1 to 30 September 2021 were used to compare vaccine effectiveness between the ′early′ group (fully vaccinated in April to June 2021) and the ′late′ group (fully vaccinated in Jul to Aug 2021). We used a negative binomial regression model to estimate vaccine effectiveness against COVID-19 infections for both ′early′ and ′late′ groups, by comparing the rates of infection for individuals vaccinated in the two different periods relative to the unvaccinated. Among confirmed COVID-19 cases, we used logistic regression to estimate and compare vaccine effectiveness against ICU admission and deaths between the two different periods. For BNT162b2, vaccine effectiveness against COVID-19 infections declined from 90.8% (95% CI 89.4, 92.0) in the late group to 79.1% (95% CI 75.8, 81.9) in the late group. Vaccine effectiveness for BNT162b2 against ICU admission and deaths were comparable between the two different periods. For CoronaVac, vaccine effectiveness waned against COVID-19 infections from 74.4% in the late group (95% CI 209 70.4, 77.8) to 30.0% (95% CI 18.4, 39.9) in the early group. It also declined significantly against ICU admission, dropping from 56.1% (95% CI 51.4, 60.2) to 29.9% (95% CI 13.9, 43.0). For deaths, however, CoronaVac′s effectiveness did not wane after three to five months of full vaccination. Vaccine effectiveness against COVID-19 infections waned after three to five months of full vaccination for both BNT162b2 and CoronaVac in Malaysia. Additionally, for CoronaVac, protection against ICU admission declined as well. Evidence on vaccine effectiveness over time informs evolving policy decisions on vaccination.
After excluding individuals with infections outside of the study period and recipients of other vaccines, 9,927,350 individuals were fully vaccinated with homologous BNT162b2 or CoronaVac vaccines. There were 246,029 confirmed COVID-19 cases throughout the outcome observation period in September 2021, of which 163,902 were vaccinated, and 82,127 were unvaccinated. For BNT162b2, overall vaccine effectiveness against ICU admission and death were largely similar between the late and early groups. Overall vaccine effectiveness against ICU admissions dropped slightly from 86·0% (95% CI 82·8, 88·6) in the late group to 79·3% (95% CI 74·3, 83·4) in the early group. When stratified by age groups, the decline was stronger among cases aged 60 years and above, for which effectiveness fell to 57·2% (95% CI 43·4, 67·6). For deaths, vaccine effectiveness among both early and late groups remained at around 90%, suggesting no waning of effectiveness. When stratified by age, effectiveness against death among cases aged 60 years and above was lower than the other age groups, but similarly did not wane.For CoronaVac, vaccine effectiveness waned for ICU admissions, but remained stable against deaths. Moreover, CoronaVac’s effectiveness estimates were generally lower compared to BNT162b2. For ICU admissions, vaccine effectiveness declined from 56·1% (95% CI 51·4, 60·2) in the late group to 29·9% (95% CI 13·9, 43·0) in the early group. The waning of effectiveness against ICU admissions was observed in all age groups. In contrast, vaccine effectiveness against death remained at above 75%. The age-stratified analysis shows that CoronaVac’s effectiveness against death remained stable for the older age groups (40 to 59 years old, 60 years and above), while for those aged 18 to 39 years old, the number of deaths were too small to estimate reliably.
![[community profile]](https://www.dreamwidth.org/img/silk/identity/community.png){kind=small}
no subject
Date: 2022-01-17 12:45 pm (UTC)Спасибо. Вот статистика наконец.
no subject
Date: 2022-01-17 09:45 pm (UTC)Спасибо!
no subject
Date: 2022-01-18 01:59 am (UTC)Малайзия и та считает, данные собирает. а США?..